

**CENTER FOR DRUG EVALUATION AND  
RESEARCH**

*APPLICATION NUMBER:*  
**022036Orig1s000**

**REMS**

## Appendix A

**NDA 22-036**

**SILENOR<sup>®</sup> (doxepin) Tablets**  
**Selective Histamine H<sub>1</sub> Antagonist**

**Somaxon Pharmaceuticals, Inc.**  
**3830 Valley Centre Drive, Suite 705-461**  
**San Diego, CA 92130**  
**858-480-0400**

**RISK EVALUATION AND MITIGATION STRATEGY**  
**(REMS)**

### **I. GOAL**

The goal of this REMS is to inform patients about the serious risks associated with the use of Silenor<sup>®</sup>.

### **II. REMS ELEMENTS**

#### **A. Medication Guide**

Somaxon Pharmaceuticals, Inc., in accordance with 21 CFR 208.24(b), will make the currently approved Medication Guide (See 1.14.1.3 Draft Labeling Text) available for distribution to patients to be dispensed with each Silenor prescription. The Medication Guide will be provided in sufficient numbers to meet the dispenser obligations under 21 CFR 208.24(e). Silenor is packaged as unit of use in a 30-ct bottle or 30-ct blister dose pack and is packaged for pharmacy dispensing in a 100-ct and 500-ct bottle.

The Medication Guide will be attached as part of the top insert of the primary packaging for the 30-ct bottle and will be inserted into the sleeve of the 30-ct blister dose pack. Additionally, for product packaged in either the 100-ct or 500-ct bottle configurations, the Medication Guide will be made available to the pharmacist to include with the prescription at the time the product is dispensed to the patient.

In accordance with CFR 208.24(d) a statement will be included on the container label for Silenor to instruct the pharmacist to dispense the Medication Guide with each prescription of the product.

#### **B. Timetable for Submission of Assessments**

Somaxon Pharmaceuticals will submit REMS Assessments to FDA 18 months, 3 years, and 7 years from the date of the approval of the REMS. To facilitate inclusion of as much information as possible while allowing reasonable time to prepare the submission, the reporting interval covered by each assessment should conclude no earlier than 60 days

before the submission date for that assessment. Somaxon Pharmaceuticals will submit each assessment so it will be received by the FDA on or before the due date.

**Medication Guide:**

**MEDICATION GUIDE**

**SILENOR<sup>®</sup> (SI-leh-nor) Tablets**

*(doxepin)*

Read this Medication Guide before you start taking SILENOR and each time you get a refill. There may be new information. This information does not take the place of talking to your healthcare provider about your medical condition or treatment.

---

**What is the most important information I should know about SILENOR?**

**After taking SILENOR, you may get up out of bed while not being fully awake and do an activity that you do not know you are doing. The next morning, you may not remember that you did anything during the night.** You have a higher chance for doing these activities if you drink alcohol or take other medicines that make you sleepy with SILENOR. Reported activities include:

- driving a car ("sleep-driving")
- making and eating food
- talking on the phone
- having sex
- sleep-walking

**Call your healthcare provider right away if you find out that you have done any of the above activities after taking SILENOR.**

**Important:**

### **1. Take SILENOR exactly as prescribed**

- Do not take more SILENOR than prescribed.
- Take SILENOR 30 minutes before bedtime. After taking SILENOR, you should only do activities needed to get ready for bed.

### **2. Do not take SILENOR:**

- with alcohol
  - if you take other medicines that can make you sleepy. Talk to your healthcare provider about all of your medicines. Your healthcare provider will tell you if you can take SILENOR with your other medicines.
  - if you cannot get a full night of sleep before you must be active again
- 

### **What is SILENOR?**

SILENOR is a hypnotic (sleep) medicine that is used to treat people who have trouble staying asleep.

### **Who should not take SILENOR?**

Do not take SILENOR if you:

- take a monoamine oxidase inhibitor (MAOI) medicine or have taken an MAOI in the last 14 days (2 weeks). Ask your healthcare provider if you are not sure if your medicine is an MAOI.
- have an eye problem called narrow angle glaucoma that is not being treated
- have trouble urinating
- are allergic to any of the ingredients in SILENOR. See the end of this Medication Guide for a complete list of ingredients in SILENOR.

Talk to your healthcare provider before taking this medicine if you have any of these conditions.

It is not known if SILENOR is safe and effective in children.

**What should I tell my healthcare provider before taking SILENOR?**

**Before you take SILENOR, tell your healthcare provider if you:**

- See “Who should not take Silenor”
- have a history of depression, mental illness, or suicidal thoughts
- have severe sleep apnea.
- have kidney or liver problems
- have a history of drug or alcohol abuse or addiction
- have a history of glaucoma or urinary retention
- have any other medical conditions
- are pregnant or plan to become pregnant. It is not known if SILENOR will harm your unborn baby. Talk to your healthcare provider if you are pregnant or plan to become pregnant.
- are breast-feeding or plan to breast-feed. SILENOR can pass into your milk and may harm your baby. Talk to your healthcare provider about the best way to feed your baby if you take SILENOR. You should not breast-feed while taking SILENOR.

Tell your doctor about all of the medicines you take including prescription and nonprescription medicines, vitamins and herbal supplements.

SILENOR and other medicines may affect each other causing side effects. SILENOR may affect the way other medicines work, and other medicines may affect how SILENOR works.

Especially tell your healthcare provider if you take:

- a monoamine oxidase inhibitor (MAOI). See “Who should not take SILENOR?”
- cimetidine (Tagamet) or other medicines that can affect certain liver enzymes
- certain allergy medicines (antihistamines) or other medicines that can make you sleepy or affect your breathing
- the diabetes medicine tolazamide

Ask your doctor or pharmacist if you are not sure if your medicine is one that is listed above.

Know the medicines you take. Keep a list of your medicines with you to show your doctor and pharmacist each time you get a new medicine.

### **How should I take SILENOR?**

- Take SILENOR exactly as your healthcare provider tells you to take it
- Your doctor will tell you how many SILENOR to take and when to take them.
- Your doctor may change your dose if needed.
- **Take SILENOR within 30 minutes of bedtime.** After taking SILENOR, you should confine your activities to those necessary to prepare for bed.
- Do not take SILENOR within 3 hours of a meal. Silenor may not work as well, or may make you sleepy the next day if taken with or right after a meal..
- **Do not take SILENOR unless you are able to get a full night of sleep before you must be active again.**
- **Call your doctor if your sleep problems get worse or do not get better within 7 to 10 days.** This may mean that there is another condition causing your sleep problem.
- If you take too much SILENOR, call your doctor or get medical help right away.

### **What should I avoid while taking SILENOR?**

- You should not drink alcohol while taking SILENOR. Alcohol can increase your chances of getting serious side effects with SILENOR.
- You should not drive, operate heavy machinery, or do other dangerous activities after SILENOR.

**You may still feel drowsy the next day after taking SILENOR. Do not drive or do other dangerous activities after taking SILENOR until you feel fully awake.**

### **What are the possible side effects of SILENOR?**

SILENOR can cause serious side effects including:

- See **“What is the most important information I should know about SILENOR?”**

The most common side effect of SILENOR is: drowsiness or tiredness

Tell your healthcare provider if you have any side effect that bothers you or that does not go away.

These are not all the possible side effects of SILENOR. For more information ask your healthcare provider or pharmacist. **Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.**

### **How should I store SILENOR?**

- Store SILENOR at 68° and 77° F (20° to 25°C).
- Keep SILENOR in a tightly closed container, and away from light. Safely throw away medicine that is out of date or no longer needed.
- **Keep SILENOR and all medicines out of the reach of children.**

## **General Information about SILENOR**

Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use SILENOR for a condition for which it was not prescribed. Do not share SILENOR with other people, even if you think they have the same symptoms that you have. It may harm them.

This Medication Guide summarizes the most important information about SILENOR. If you would like more information, talk with your healthcare provider. You can ask your healthcare provider or pharmacist for information about SILENOR that is written for healthcare professionals.

For more information, contact Somaxon Pharmaceuticals, Inc. at 1-877-745-3667 or visit <http://www.silenor.com>.

## **What are the ingredients in SILENOR?**

**Active Ingredient:** doxepin hydrochloride

**Inactive Ingredients:** Microcrystalline cellulose, colloidal silicon dioxide, colloidal anhydrous silica, light anhydrous silicic acid, and magnesium stearate. The 3 mg tablet also contains FD&C Blue No. 1. The 6 mg tablet also contains FD&C Yellow No. 10 and FD&C Blue No. 1.

Manufactured for:

Somaxon Pharmaceuticals, Inc.

San Diego, CA 92130 USA

This Medication Guide has been approved by the U.S. Food and Drug Administration.

Application Type/Number	Submission Type/Number	Submitter Name	Product Name
NDA-22036	ORIG-1	SOMAXON PHARMACEUTICA LS INC	SILENOR (DOXEPIN HCL)

---

**This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.**

---

/s/

---

CATHLEEN B MICHALOSKI  
03/17/2010

RUSSELL G KATZ  
03/17/2010